Is More PRP Better? What the Research Actually Says About Platelet Dose
If you have called around about PRP for your knee, someone has probably told you their preparation is “high concentration,” as though that settles it. It is a reasonable-sounding pitch. More platelets, more growth factors, better healing.
The research does not support the pitch, and the way it fails is more interesting than a simple yes or no. The best available evidence points to a middle band — a dose window — where outcomes look strongest, with less benefit both below it and, notably, above it. Here is what that means in plain English, and what to ask before you book.
Concentration and dose are not the same number
This is the confusion underneath almost every marketing claim you will encounter, so it is worth thirty seconds.
Concentration is how densely packed the platelets are — often quoted as a multiple of your normal blood level, like “5 times baseline.” Total delivered dose is how many platelets actually end up in your joint: concentration multiplied by the volume injected.
Those come apart easily. A very concentrated preparation in a small volume can deliver fewer platelets than a moderately concentrated one in a larger volume. When a clinic quotes you a concentration multiple and nothing else, you have been given half of the equation.
What happened when researchers counted the platelets actually delivered
A 2025 systematic review and meta-analysis in PM&R did something most previous work had not: instead of sorting trials by concentration, it sorted them by the total number of platelets delivered into the joint. Across 32 randomized controlled trials, the authors grouped PRP injections into three bands — low (1 to 5 billion total deliverable platelets), moderate (5 to 10 billion), and high (more than 10 billion).1
Compared with hyaluronic acid injections, all three bands produced significant improvement on validated patient-reported outcomes. But the effect sizes separated. The low band produced a moderate effect (standardized mean difference 0.47, 95% CI 0.05 to 0.89) and the high band likewise a moderate effect (SMD 0.68, 95% CI 0.26 to 1.09). Only the moderate band produced a large effect (SMD 1.48, 95% CI 0.71 to 2.58).
The authors own conclusion is the part worth reading twice: compared with hyaluronic acid, platelet counts between 1 and 10 billion may produce a larger decrease in pain at 6 months than counts above 10 billion, and counts between 5 and 10 billion may be associated with greater functional improvement. Compared with saline, all three bands produced large effects on pain.
Read plainly: past a point, adding more platelets did not add more benefit — and on these measures, the highest-dose group did not lead.
Why this reconciles two studies that looked like they contradicted each other
We wrote recently about why PRP results vary so much between patients, and about an unresolved split in the evidence on concentration. A 2025 meta-analysis in The American Journal of Sports Medicine pooled 18 randomized trials and 1,995 patients and found that preparations above roughly 1,000,000 ± 20% platelets/µL reached a clinically meaningful pain threshold where weaker preparations did not.2 A larger 2026 network meta-analysis in Knee Surgery & Related Research, covering 56 trials and 5,251 patients, found no statistical superiority for high-platelet formulations over low-platelet ones.3
A dose window explains both. If there is a floor you need to clear, then comparing preparations that fall below it against ones above it will show a difference — which is roughly what the 2025 analysis found. And if the benefit flattens or falls off above the window, then lumping every “high-platelet” preparation together and comparing it with everything else will wash the difference out — which is roughly what the 2026 analysis found.
Neither study was wrong. They were cutting the same curve in different places. That is a normal stage in how evidence matures, and it is a better reason to ask specific questions than to pick whichever study a clinic quotes at you.
What to ask a clinic, and what a good answer sounds like
- How many platelets does your preparation actually deliver, not just how concentrated is it? The honest answer involves both a concentration and a volume. A clinic that has never measured it should say so rather than quote you a marketing number.
- Do you know your systems output, or are you relying on the manufacturers brochure? Yield varies between patients and between draws. Brochure figures are a starting point, not a measurement.
- What are you optimizing for? Anyone promising you the largest possible dose is optimizing for something the evidence does not currently reward.
- What happens if the first injection does not help? A plan that has an answer to this is a better plan.
We will be straightforward about our own position. Venturis has not published a measured total deliverable platelet count for our preparation, so we are not going to claim we hit any particular band — and you should be skeptical of any clinic that makes that claim without data behind it. What we can tell you is how your specific preparation is made and what we are aiming for, during a consultation. If you want the broader picture first, our overview of PRP therapy and of prolotherapy covers how each is used.
Who is generally not a good candidate
Dose is a secondary question if the treatment is not appropriate in the first place. Candidates are typically evaluated for the following during a consultation:
- Active infection, at the injection site or systemically.
- Platelet or bleeding disorders, or anticoagulation that cannot be safely managed around the procedure.
- Active malignancy. These decisions belong with your oncology team.
- Severe, end-stage joint changes where a surgical plan is already underway. Some patients want to explore options before surgery; that is a reasonable conversation, and it is not the same as replacing a decision already made with a surgeon.
- Anyone who wants a guaranteed number. The research describes averages across trials. It cannot tell you what your knee will do.
Frequently asked questions
Is a higher platelet count better in PRP?
Not necessarily. In a 2025 meta-analysis of 32 randomized trials, the largest effect came from the moderate band of 5 to 10 billion total deliverable platelets, and doses above 10 billion did not outperform lower doses for pain at 6 months. More is not automatically better.
What is a total deliverable platelet dose?
It is the number of platelets actually injected into the joint — the concentration of the preparation multiplied by the volume delivered. It is a different measurement from the concentration multiple most clinics advertise.
How many platelets should a PRP injection contain?
The published evidence points toward a range rather than a target. In the 2025 analysis, 1 to 10 billion total deliverable platelets was associated with greater pain reduction at 6 months than doses above 10 billion, with 5 to 10 billion associated with better functional outcomes. What is appropriate for an individual patient is a clinical decision, not a formula.
Why do PRP studies disagree about concentration?
Largely because they cut the same dose-response curve in different places. One analysis compared preparations above and below roughly 1,000,000 platelets/µL and found a difference; a larger one compared high-platelet against low-platelet formulations and found none. A middle-band effect is consistent with both.
Does the volume injected matter?
It matters because it is half of the dose calculation. The same concentration delivered in a larger volume puts more platelets into the joint, which is why concentration alone does not tell you what you received.
Should I ask my clinic what dose they use?
Yes, and the quality of the answer is informative on its own. A clinic that can explain its preparation and its volume is telling you something different from one that only quotes a concentration multiple.
Is PRP FDA-approved for knee osteoarthritis?
No. The centrifuge systems used to prepare PRP are FDA-cleared devices, but PRP itself is not FDA-approved as a treatment for knee osteoarthritis.
How long before I would know whether it worked?
The trials in this literature commonly measure outcomes at 3, 6, and 12 months. Patients may experience gradual change over weeks rather than days, and results vary.
Ask us the specific questions
If you are comparing clinics, the questions above are worth asking all of them, including us. Dr. Alvin Philipose has practiced regenerative and functional medicine in Oklahoma City for more than 25 years. Book a free 15-minute phone consultation, or request an appointment for a full evaluation. You can also call the clinic at (405) 848-7246.
Venturis Clinic
7917 N May Ave, Suite B
Oklahoma City, OK 73120
(405) 848-7246
Monday–Thursday, by appointment
Serving Oklahoma City, Edmond, Norman, Moore, Yukon, Mustang, Piedmont, Bethany, Warr Acres, and Nichols Hills.
This content is for educational purposes only and is not medical advice, diagnosis, or treatment. Individual results vary and no outcome is guaranteed. Venturis Clinic offers regenerative, functional, and alternative medicine services; some therapies discussed are not FDA-approved for the uses described. Talk with a qualified healthcare provider about your specific situation before beginning any treatment.
Sources
- Hooper N, Shapiro S, Paidsetty V, Azarpey A, Jindal A, Mautner K, Easley K, Buford D, Sussman W, Jayaram P. Platelet-rich plasma outcomes in knee osteoarthritis are associated with the amount of total deliverable platelets: a systematic review and meta-analysis. PM&R. 2025;18(2):210–222. DOI: 10.1002/pmrj.13455
- Bensa A, Previtali D, Sangiorgio A, Boffa A, Salerno M, Filardo G. PRP injections for the treatment of knee osteoarthritis: the improvement is clinically significant and influenced by platelet concentration: a meta-analysis of randomized controlled trials. The American Journal of Sports Medicine. 2025;53(3):745–754. DOI: 10.1177/03635465241246524
- Anitua E, Padilla S, Prado R, Tierno R, Alkhraisat MH. Influence of platelet-rich plasma composition on pain and functional performance in knee osteoarthritis: a systematic review and network meta-analysis. Knee Surgery & Related Research. 2026;38(1):17. DOI: 10.1186/s43019-026-00318-4
